Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study

Purpose: To determine the efficacy and safety of adalimumab (ADA) and etanercept (ETA) biosimilars in elderly and children with psoriasis. Methods: A real-life retrospective observational study was conducted on pediatric (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Psoriasis (Auckland, New Zealand) New Zealand), 2022-07, Vol.12, p.199-204
Hauptverfasser:	Megna, Matteo, Fornaro, Luigi, Potestio, Luca, Luciano, Maria Antonietta, Nocerino, Mariateresa, Delfino, Mario, Guarino, Maria, Fabbrocini, Gabriella, Camela, Elisa
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Aged patients Arthritis Biological products biosimilar Care and treatment Clinical trials Comorbidity COVID-19 Dermatologic agents Dermatology etanercept Formulae, receipts, prescriptions Geriatrics Health care access Monoclonal antibodies Older people Original Research Patients Pediatrics Population Psoriasis Psoriatic arthritis TNF inhibitors treatment Tumor necrosis factor Tumor necrosis factor-TNF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose: To determine the efficacy and safety of adalimumab (ADA) and etanercept (ETA) biosimilars in elderly and children with psoriasis. Methods: A real-life retrospective observational study was conducted on pediatric (
ISSN:	2230-326X 2230-326X
DOI:	10.2147/PTT.S365493